Beads (1)Antibody (1)
Launched (2)
Rabbit (2)
- (2)
- (1)Acridinium ester Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
AMG-S163 | HEK293 | Anti-Mouse IgG-Acridinium ester (MALS verified) | ||||
MPC-A003 | - | Anti-Mouse IgG-coupled Magnetic Beads (recommended for MPCLIA) |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Belapectin | GR-MD-02 | Phase 3 Clinical | Galectin Therapeutics Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Squamous Cell Carcinoma of Head and Neck; Fibrosis; Hypertension, Portal; Psoriasis; Hepatic Insufficiency; Esophageal and Gastric Varices; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Olitigaltin | GB-0139; TD-139 | Phase 2 Clinical | The University Of Edinburgh, Lund University Foundation | Idiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19) | Details |
| Galactomannan C | GM-CT-01 | Phase 2 Clinical | Galectin Therapeutics Inc | Head and Neck Neoplasms; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Breast Neoplasms; Prostatic Neoplasms; Coronaviridae Infections; Colorectal Neoplasms; Bile Duct Neoplasms; Lung Neoplasms; Gallbladder Neoplasms; Melanoma | Details |
| Selvigaltin | GB-1211; GB1211 | Phase 2 Clinical | Galecto Inc | Squamous Cell Carcinoma of Head and Neck; Metabolic Dysfunction-Associated Steatotic Liver Disease; Hepatic Insufficiency; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| ProLectin-M | Phase 2 Clinical | BioXyTran Inc | Cytokine Release Syndrome; Coronavirus Disease 2019 (COVID-19); Influenza, Human | Details | |
| Gal-400 | Gal-400 | Phase 1 Clinical | Galecto Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ocriplasmin | A-01016; THR-409 | Approved | Thrombogenics | Jetrea, Jejetrea | United States | Vitreomacular Adhesion | Thrombogenics Inc | 2012-10-17 | Vitreous Detachment; Arterial Occlusive Diseases; Disease Progression; Stroke; Retinal Diseases; Diabetic macular oedema; Uveitis; Vitreomacular Adhesion; Venous Thrombosis; Eye Diseases; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion | Details |

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8



